About us
ExpreS2ion is a clinical-stage biotechnology company developing active immunotherapies and other biologic drug candidates based on its proprietary ExpreS2 protein expression platform.
Our Mission
To develop differentiated immunotherapies with the potential to improve outcomes for patients with serious diseases.
Our Vision
We want to transform healthcare by developing novel immunotherapies that are lifesaving and improving quality of life around the world.
Our Approach
ExpreS2ion develops biologic drug candidates using its proprietary ExpreS2 protein expression platform. The platform uses insect cells to produce complex proteins that can support a range of therapeutic and immunology-based applications.
Our approach combines antigen and protein design, expression in the ExpreS2 system, and controlled development and manufacturing processes. This allows us to work with complex protein targets while maintaining a focus on quality, scalability, and scientific rationale.
We aim to advance differentiated drug candidates through disciplined development plans, efficient use of capital, and a clear path towards clinical and commercial value.
Team
Our team has more than 100 years of experience relevant to drug development and is committed to developing innovative immunotherapies for the world’s worst infectious diseases and cancer, channeling their expertise and passion into pioneering advancements.
Executive Management
Bent U. Frandsen
Chief Executive Officer
Keith Alexander
Chief Financial Officer
Dr. Max M. Søgaard
Chief Scientific Officer
Board of Directors
Dr. Martin Roland Jensen
Chairman
Dr. Karin Garre
Board Member
Jakob Knudsen
Board Member
Michel Baijot
Board Member
Advisory Boards
ExpreS2ion Biotechnologies boasts two distinguished scientific advisory boards: the Oncology Scientific Advisory Board and the Infectious Diseases Scientific Advisory Board.
These expert panels contribute invaluable insights, guiding the company’s research and development efforts in cancer and infectious disease immunotherapies, respectively. Their collective expertise enhances ExpreS2ion’s strategic decision-making and supports cutting-edge advancements in these critical fields.
Advisory Board - Infectious Diseases
Dr. Stanley Plotkin
MD, PhD, DMSci
Dr. Allan Randrup Thomsen
MD, DMSci
Dr. Lone Graff Stensballe
MD, PhD, DMSci
Dr. Mark Schleiss
MD
Advisory Board - Oncology
Dr. Giuseppe Curigliano
MD, PhD
Dr. Javier Cortes
MD, PhD
Dr. Ulrik Lassen
MD, PhD
Dr. Rupert Bartsch
MD
Dr. Daniel Lenihan
MD, FACC, FESC, FIC-OS
